Physician profile
John R Case
NPI 1396859039
$2,875.78
in general payments reported to CMS, 2019-2025
32 companies · $924 in 2025
The $924 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $79.25 · 2021: $153 · 2022: $357 · 2023: $411 · 2024: $531 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,865.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $392.80 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $267.35 | 2019-2025 | Erleada, Akeega, Balversa |
| Astellas Pharma US INC | $249.04 | 2019-2025 | Xtandi, Veozah |
| Endo Pharmaceuticals INC. | $207.14 | 2019-2023 | Xiaflex, Aveed |
| Blue Earth Diagnostics | $171.60 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $142.85 | 2023-2025 | |
| Pfizer INC. | $140.38 | 2019-2025 | |
| Myovant Sciences INC. | $127.85 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $113.88 | 2019-2025 | Provenge |
| Urogen Pharma, INC. | $100.57 | 2022-2025 | Jelmyto |
| Abbvie INC. | $91.24 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.60 | 2019-2025 | |
| Tolmar Pharmaceuticals, INC. | $85.14 | 2019-2022 | |
| Medtronic, INC. | $77.03 | 2024-2025 | Interstim, Nuro |
| Procept Biorobotics Corporation | $75.88 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $75.05 | 2025 | Itind System |
| Myriad Genetic Laboratories, INC. | $53.82 | 2024-2025 | Prolaris |
| Boston Scientific Corporation | $52.17 | 2023-2024 | Lithovue Empower, Tria Firm, Lumenis Pulse 120h |
| Antares Pharma, INC. | $48.54 | 2019 | |
| Accord Healthcare, INC. | $42.32 | 2025 | |
| Integra Lifesciences Corporation | $39.45 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Vertex Pharmaceuticals Incorporated | $33.02 | 2025 | |
| Merck Sharp & Dohme LLC | $31.72 | 2025 | Lynparza |
| Aytu Biopharma, INC. | $30.29 | 2019 | |
| Philips North America LLC | $30.00 | 2025 | Disease Management Solutions Equipment Undivided |
| Verity Pharmaceuticals INC. | $29.35 | 2025 | Trelstar |
| Astrazeneca Pharmaceuticals Lp | $26.38 | 2024 | Lynparza |
| Urovant Sciences INC | $20.31 | 2022 | |
| Tolmar, INC. | $20.13 | 2024 | |
| Acerus Pharmaceuticals Corporation | $11.88 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,124.48 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Case listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.